Background: has been shown to be a safe replacement for chlorofluorocarbons (CFCs) as a pharmaceutical propellant, with the advantage that it has no ozone-depleting potential. This is the first report of the pharmacokinetics of beclomethasone dipropionate (BDP) delivered from a pressurized solution formulation using an HFA propellant system (HFA-BDP) in Japanese children with bronchial asthma.
INTRODUCTION
Hydrofluoroalkane-134a (HFA) has been shown to be a safe replacement for chlorofluorocarbons (CFCs) as a pharmaceutical propellant, with the advantage that it has no ozone-depleting potential. 1 Metered dose inhalers ( MDIs ) of beclomethasone dipropionate (BDP), using CFCs as propellant system in a pressand-breathe ( P & B ) inhalation device ( CFC-BDP ) , have been used for many years in patients with bronchial asthma, but the Montreal Protocol represents international agreement to cease CFCs production and use. HFA is a suitable replacement propellant for CFCs in MDIs, as it does not deplete stratospheric ozone. The BDP solution product using HFA as propellant system (HFA-BDP) has a smaller particle size F i g . 1 I n d i v i d u a l ( ○) a n d me a n ( •) p l a s ma c o n c e n t r a t i o nt i me p r o f i l e s o f b e c l o me t h a s o n e 1 7 -mo n o p r o p i o n a t e ( 1 7 -B MP ) i n J a p a n e s e c h i l d r e n wi t h b r o n c h i a l a s t h ma f o l l o wi n g a d mi n i s t r a t i o n o f 2 0 0 μ g o f b e c l o me t h a s o n e d i p r o p i o n a t e ( B DP ) . E a c h e r r o r b a r r e p r e s e n t s t h e s t a n d a r d d e v i a t i o n . distribution (by mass) than the CFC-BDP suspension product , which results in improved intrapulmonary deposition and airway availability of HFA-BDP when compared with CFC-BDP . 2 The HFA-BDP has an equivalent effect to the twice dose of CFC-BDP 3 and has been approved and used in adult patients in numerous countries. As CFC-BDP has also been essential in the treatment of children with bronchial asthma, the indications and usage of HFA-BDP for children need to be established urgently . Although the pharmacokinetics of HFA-BDP in American children with bronchial asthma have already been reported, 4, 5 they have not yet been reported in Japanese children. The objective of this clinical trial was to clarify the pharmacokinetics of HFA-BDP in Japanese children with bronchial asthma.
METHODS
Five Japanese patients with stable mild asthma, between the ages of 6 years and 15 years (3 men and 2 women), were enrolled in this open-label study. Written informed consent was obtained from all patients and their parents or legal guardians in accordance with the Declaration of Helsinki . The independent medical ethics review committee of Gifu University approved the protocol. Each patient received 200 μg BDP per period, as four inhalations of 50 μg! actuation P & B. Time zero for each dose was defined as the time when the inhaler was first actuated. Blood samples were collected before administration, and at 0.5, 1, 2, 4, 6, 9, 12 and 24 hours after administration. Immediately after collection , the tube was inverted and the blood was cooled on ice and centrifuged at 2000 rpm for 10 minutes at 7 , and the isolated plasma was pippeted into two tubes ( 0.5 mL per tube). In each tube, 15 μL of acetic acid was added and mixed. Mixed samples were frozen immediately in a dry ice! methanol bath and stored frozen at under −70 until analysis. As almost all the BDP-derived material in plasma is reported to be the active metabolite , beclomethasone 17-monopropionate ( 17-BMP), 4 the plasma 17-BMP concentration was determined using an LC ! MS ! MS method with a lower limit of quantitation of 75 pg! mL developed by Harrison et al. 5 with a few modifications. The pharmacokinetic parameters , area under concentration-time curve from time zero to the last quantifiable time (AUC0-t), maximum concentration observed ( Cmax), time to reach Cmax (Tmax) and apparent elimination half-life ( t1 !2) were calculated by a non-compartmental analysis of each plasma concentration-time profile using WinNonlin ver.4.0 (Pharsight Corporation) . The effects of age ( 6 to 14 years ) and body weight (22.8 to 85.0 kg) on AUC0-t, Cmax and t1! 2 were analyzed by linear regression analysis of logtransformed parameters against age or body weight.
The parameters of Japanese children obtained in this study were compared with the previously reported parameters of American children with bronchial asthma provided by 3M Pharmaceuticals (USA). 6 For log-transformed parameters of AUC0-t, Cmax and t1! 2, means and their 90% confidence intervals were calculated for the differences between Japanese and American parameters and back-transformed to geometric means and their 90% confidence intervals for the ratios of Japanese parameters to American parameters . The log-transformed means of parameters were also compared by Student's t-test, considering p values of less than 0.05 to indicate statistically significant differences.
RESULTS AND DISCUSSION

PHARMACOKINETICS OF HFA-BDP IN JAPA-NESE CHILDREN WITH BRONCHIAL ASTHMA
The individual plasma concentration profiles of 17-BMP in Japanese children with bronchial asthma and their mean profile are shown in Figure 1 . Pharmacokinetic parameters are shown in Table 1 . The arithmetic mean ± standard deviation (SD) of AUC0-t was 1659 ± 850 pg h! mL, Cmax was 825 ± 453 pg! mL and t1! 2 was 2.1 ± 0.7 hours. Tmax was 0.5 hours in all patients. The coefficient of variability of AUC0-t and Cmax (51.2% and 54.9%, respectively) was larger than that of t1! 2 (31.4%), which indicated a higher variability of the rate and extent of absorption than the elimination rate, possibly because of variability in the patients' inhalation techniques. No significant effect of age (6 to 14 years) or body weight (22.8 to 85.0 kg) on pharmacokinetic parameters was observed ( Table 2 , p = 0.145). This result suggests that no dose adjustment F i g . 2 J a p a n e s e (• ) a n d A me r i c a n (○ ) p l a s ma c o n c e n t r a t i o n -t i me p r o f i l e s o f b e c l o me t h a s o n e 1 7 -mo n op r o p i o n a t e ( 1 7 -B MP ) f o l l o wi n g a d mi n i s t r a t i o n o f 2 0 0 μ g b ec l o me t h a s o n e d i p r o p i o n a t e ( B DP ) . E a c h p o i n t r e p r e s e n t s t h e me a n ± s t a n d a r d d e v i a t i o n o f 5 J a p a n e s e o r 1 8 A me r ic a n c h i l d r e n wi t h b r o n c h i a l a s t h ma . 
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COMPARISON OF HFA-BDP PHARMACOKINET-ICS BETWEEN JAPANESE AND AMERICAN CHILDREN WITH BRONCHIAL ASTHMA
The plasma concentration profiles of 17-BMP in Japanese and American children with bronchial asthma following a 200 μg BDP dose using the HFApropellant system are shown in Figure 2 . Pharmacokinetic parameters and their ratios ( Japanese ! American) are shown in Table 3 . The differences of log-transformed mean 17-BMP parameters ( AUC0-t, Cmax and t1! 2) between Japanese and Americans were not significant (p = 0.13 ). The median of Tmax in American children was the same as that in Japanese children. The estimated Japanese! American AUC0-t ratio was 1.36 with a 90% confidence interval of 0.870 to 2.13. The estimated Japanese! American Cmax ratio was 1.04 with a 90% confidence interval of 0.671 to 1.62. The estimated Japanese! American t1! 2 ratio was 1.4 with a 90% confidence interval of 0.96 to 1.9. All confidence intervals contained 1, suggesting the possibility of the equivalence of the parameters between Japanese and Americans. The wide confidence intervals obtained may be due to variability in patients' inhalation techniques, and an insufficient limit of quantitation, which may affect the last quantifiable timepoint and the apparent elimination half-life.
In conclusion, the pharmacokinetics of HFA-BDP
